Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NUf1c4l{S2WubDDWbYFjcWyrdImgRZN{[Xl? NFrqWJMzNjVvMUWgcm0> Ml3JO|IhcA>? MoLLbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MVmyOVc6ODlyNx?=
U2932  NXXUepBRS2WubDDWbYFjcWyrdImgRZN{[Xl? NGfZdIczNjVvMUWgcm0> M2DhNFczKGh? NHfSbZJqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M1PVZlI2PzlyOUC3
OCI-LY7 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHrOXGUzNjVvMUWgcm0> NXrnUJN4PzJiaB?= Ml[xbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MVSyOVc6ODlyNx?=
Farage MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M17DdVIvPS1zNTDuUS=> NHfEUFk4OiCq MmPhbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MVGyOVc6ODlyNx?=
LY7/EBV MoD3R4VtdCCYaXHibYxqfHliQYPzZZk> Ml;vNk42NTF3IH7N MXG3NkBp NVrwVIN3cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MV:yOVc6ODlyNx?=
U2932/EBV MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYqyMlUuOTVibl2= NWC2NZo4PzJiaB?= MWrpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MkDZNlU4QTB7MEe=
HCT116 M4HjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK1OlE2NTVyMECgcm0> NYXVTnNHOjRiaB?= M4W2SWROW09? MWnpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MVmyOVQ6OjVzNR?=
ACH-2 MYnGeY5kfGmxbjDBd5NigQ>? MkGyNU06KG6P MVSyOEBp MliybY5lfWOnczDITXYuOSCHbo[g[ZhxemW|c3nvci=> MlnTNlUyPDl2Nke=
MCF-10A MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\QR2lEPTB;MD6xO:KyOC5yMTDuUS=> NYflfIFnOjR7NUS4OVY>
MCF-7 NEXJSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PTTWlEPTB;MT6xNOKyOC5{MDDuUS=> NUPM[3VkOjR7NUS4OVY>
SK-BR-3 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwMEFCtVAvOzVibl2= NE\q[oMzPDl3NEi1Oi=>
MDA-MB-231 NXXOeGxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDYTWM2OD1yLk[4xtExNjF2IH7N NGX2eZMzPDl3NEi1Oi=>
PC3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjJTWM2OD1zLk[1xtExNjN3IH7N MkHKNlQ6PTR6NU[=
HCT116 NXjTXVBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwMEFCtVAvODBibl2= NFTId5QzPDl3NEi1Oi=>
HCT116-p21-/- MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;ufpBLUUN3ME2xMlI3yrFyLkO3JI5O MoTtNlQ6PTR6NU[=
S1 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTdwNkhCtVAvOjlibl2= M3LNSVI1QTV2OEW2
SW620 M{GyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwOURCtVAvOjlibl2= MUOyOFk2PDh3Nh?=
LOX-IMVI M3rnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TOfGlEPTB;MD64O:KyOC5yMzDuUS=> MknGNlQ6PTR6NU[=
UACC-62 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHniSZJKSzVyPUCuOVbDuTBwMU[gcm0> M{\3TlI1QTV2OEW2
MDA-MB-435 NIrZ[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrGbI9yUUN3ME2wMlkxyrFyLkC2JI5O M{WzfFI1QTV2OEW2
SF-295 NX61Z4JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j5R2lEPTB;MD64POKyOC5zNTDuUS=> MlLGNlQ6PTR6NU[=
A549 NHu4bYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nN[WlEPTB;MT6yOuKyOC5{NDDuUS=> MWCyOFk2PDh3Nh?=
H460 NVPieWVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXMN4dKSzVyPUKuOVjDuTBwOECgcm0> NHLBVHYzPDl3NEi1Oi=>
EKVX MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwM{RCtVAvOzRibl2= MnjRNlQ6PTR6NU[=
H146 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMkNCtVAvODdibl2= NHm4[HYzPDl3NEi1Oi=>
H526 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2zTWM2OD1yLkG1xtExNjB|IH7N NGXtcHEzPDl3NEi1Oi=>
HuT-78 NUHsWmFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwN{RCtVAvPDRibl2= M3vn[FI1QTV2OEW2
HA NWWyVItMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG0O3MxNjZ{NT2xNI5O M12zTVQ5KGh? Mmn4bY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MYqyOFc4OTVzMB?=
MS-275 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXewMlYzPS1zMH7N Mnf2OFghcA>? MoD4bY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> M3j3ZlI1PzdzNUGw
CD4 T MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYS0PEBp MUjFR|UxRTRwNdMxNU4xKG6P MlTxNlQ4OjJ2NUS=
CD4 T M1HhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO0SGg1QCCq M3nzNmNEPTB;MUC3xtEyOjZibl2= M4CyOVI1PzJ{NEW0
CD4+ T M2TYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrYc|VGSzVyPUOgcm0> M3v1VVI1PDl3MUC1
A549 NYHiOHdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxNQKBmzFyMNMgcm0> Mkj3NlQwOzZxNEigbC=> MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NECyNIwzPDR6NUe5PS=>
JJN3 NXnmb2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKyOE81QCCq NWfsOHM2TUN3MEyx5qCKdk19IES45qCKcA>? MVuyOFA{ODF3MB?=
OPM-2 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWyOE81QCCq M1HpcWVEPTC|PUJihKlvVTtiNElihKlp NVmxSGZIOjRyM{CxOVA>
RPMI-8226 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXheHIzPC92ODDo MmHnSWM2OHN;MT645qCKdk19IES45qCKcA>? M3rEZVI1ODNyMUWw
U266 M1P5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInVeJgzPC92ODDo MmjDSWM2OHN;MUFihKlvVTtiNElihKlp MW[yOFA{ODF3MB?=
CA46 NEnEPFNCeG:ydH;zbZMhSXO|YYm= Mo\yOkBp NH3UOlJqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MnLENlM6PjZzNkS=
DG75 NHTQe4xCeG:ydH;zbZMhSXO|YYm= MlPHOkBp NHPnWpRqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? M3LicFI{QTZ4MU[0
Ramos MmD6RZBweHSxc3nzJGF{e2G7 MX[2JIg> NWXhdnJXcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NIn0VYUzOzl4NkG2OC=>
ST486 M2W4UmFxd3C2b4Ppd{BCe3OjeR?= NFnaSVg3KGh? NV\MSZk4cW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ M3PPWVI{QTZ4MU[0
HuT78 Mmm3RZBweHSxc3nzJGF{e2G7 NF3xS|EyNzFyL{GwNEBvVQ>? M1\Qc|Q5KGh? Mmj0bY5lfWOnczDhdI9xfG:|aYOgZZQhOSCwTR?= NEHoU2UzOzV|MkezNi=>
DpVp35 M363SmFxd3C2b4Ppd{BCe3OjeR?= M4\0OVEwOTBxMUCwJI5O NWfIS2hEPDhiaB?= MlfTbY5lfWOnczDicJVvfCCjcH;weI9{cXN? NEeydXMzOzV|MkezNi=>
DpVp50 NWnEWFh1SXCxcITvd4l{KEG|c3H5 Mk\xNU8yOC9zMECgcm0> NYXyeY9NPDhiaB?= NVLpb4tMcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MnO2NlM2OzJ5M{K=
DpP75  NU\xclBRSXCxcITvd4l{KEG|c3H5 NYfnbJZNOS9zMD:xNFAhdk1? MYi0PEBp NHXBWXlqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MUKyN|U{Ojd|Mh?=
SKOV-3 NWLzO4lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPqdmky6oDVMkDuUS=> NYnjc4toPzJiaB?= M4S1[GROW09? MlXFdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NIPQeJIzOzBzMEO0PC=>
Brca1 WT MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvkO|dtOeLCk{Kwcm0> MlKyO|IhcA>? MXrEUXNQ M{PLcZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NH;NdYczOzBzMEO0PC=>
Brca1 Null MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrhNgKBmzJybl2= NGLHe2c4OiCq M2XZbWROW09? MlLCdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> Mo\KNlMxOTB|NEi=
OVCAR-8  MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr4cZYy6oDVMkDuUS=> MVi3NkBp NVPMTm9{TE2VTx?= NYO3TnRkemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NH:4e40zOzBzMEO0PC=>
NCI/ADR-RES MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGx5qCUOjCwTR?= M2PDZlczKGh? NGi5eZFFVVOR M{LzNZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MYmyN|AyODN2OB?=
HCT116 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHxOUBvVS13MDFOwG0> MoPDNlQhcA>? NVjFVlE1TE2VTx?= NXyzOJpjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NYfTW4xMOjJ7MkS5OVg>
RKO MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV61JI5ONTVyIN88US=> NVHG[pJ4OjRiaB?= NGG1SIpFVVOR MkXKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NVXTU2RVOjJ7MkS5OVg>
CO115 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWK1JI5ONTVyIN88US=> NFPRZWYzPCCq MYTEUXNQ NXnqdYlDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NIXlcmMzOjl{NEm1PC=>
HFS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO1Xpp6PSCwTR?= MXOyOE81QC95MjDo NGnPO5NqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MUWyNlExPjJ6Mh?=
LNCaP M2fHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjHTI1XPSCwTR?= NVftfXJQOjRxNEivO|IhcA>? M1vVNolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NIfSXVgzOjFyNkK4Ni=>
A549 NUGwcJNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWi1JI5O MnvBNlQwPDhxN{KgbC=> M4nSe4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NHfVO5MzOjFyNkK4Ni=>
697  NVG4cW97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nZZ2lEPTEkgJm95qCKOi53wrDuUS=> MUOyNVU{QDJzNh?=
697-R NUDNOYxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OOLCiU5ihKk5NjcEoH7NxsA> NXnkS41WOjF3M{iyNVY>
HUT78 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXHTWM2OD1zIH7N M1jPdFIyOTl6NUS1
THJ-16T M3vYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rYTFEhdk1? MXmyOEBp M{m3SolvcGmkaYTzJINmdGxiZ4Lve5Rp M2HlO|IxQDFyNU[4
HCT116 MWDGeY5kfGmxbjDBd5NigQ>? MlHYNlAhdk1? NU\VTYpsQCCq MUjtc4R2dGG2ZYOgeJJidnOlcnnweEBt\X[nbIOg[o9zKGi3bnTy[YR{KG:oIHflcoV{KGmwIHXpeIhmeiCmaYLlZ5Rqd25? Mlu4NlA4Ozl2NUS=
B104  MlvxSpVv[3Srb36gRZN{[Xl? NWHJWpBJOiCwTR?= MlPlNlQwPDhxN{KgbC=> MYXpcoNz\WG|ZYOgeIhmKHO3cn\hZ4Uh\XiycnXzd4lwdiCxZjDDSFIxyqB? MoTlNlA3QDZ3MEW=
HL-60  MV;DfZRwfG:6aXPpeJkhSXO|YYm= M2XUXlEuPTByIH7N MV6yOEBp NHTSNFFqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M1jLRlIxPjJ2MU[z
HP100 MlzjR5l1d3SxeHnjbZR6KEG|c3H5 M4G5UVEuPTByIH7N NW\VOWl7OjRiaB?= NVi0dohIcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MYmyNFYzPDF4Mx?=
HL-60  M4P3T2Z2dmO2aX;uJGF{e2G7 M2\sU|ExKG6P M4Kwd|QwPi9zNjDo MW\pcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? M1HSSlIxPjJ2MU[z
HP100 NFT0d5pHfW6ldHnvckBCe3OjeR?= MlrYNVAhdk1? MXK0M|YwOTZiaB?= MYnpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? NHPXc3IzODZ{NEG2Ny=>
HL-60  MV\GeY5kfGmxbjDBd5NigQ>? M1u4S|ExNTVyMDDuUS=> NEfWeZc1KGh? NXL0NGRM\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg NYHKeHlIOjB4MkSxOlM>
HP100 NHnrNmpHfW6ldHnvckBCe3OjeR?= MVqxNE02ODBibl2= M1\KbFQhcA>? Mkjj[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi M3yxVVIxPjJ2MU[z
11z MXzLbY5ie2ViQYPzZZk> NVzWZWJSOy1zMECgcm0> Mm\RdoVlfWOnczDISGFEKGWweontZZRq[yCjY4Tpeol1gSBqSVO1NOKhRSB4LkWgxtEhOC54IH7tc4wwVCl? MmnGNlA3ODVzNES=
SKOV-3 NEL3RYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj4bVA1NzhxMU[gcm0> NVraXIlwPDhiaB?= MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MX2yNFQxPDV4NB?=
OVCAR-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XTV|QwQC9zNjDuUS=> NVXoS|FuPDhiaB?= M4m0eIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MXeyNFQxPDV4NB?=
HBL-2 NHzDUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XlclIuOTBibl2= MXKyOEBp MmHiTWM2OD12LkOgcm0> MXiyNFA3QDB6MB?=
Jeko-1 M3\R[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[0c|IuPTBibl2= MorhNlQhcA>? NHzYTGFKSzVyPUGxJI5O NEnFOmczODB4OEC4NC=>
Granta-519 MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\4SJVCPS12MDDuUS=> MXmyOEBp NYj1d5E6UUN3ME21PE42KG6P M4PkNlIxODZ6MEiw
L1236 NX3PfWhwS3m2b4TvfIlkcXS7IFHzd4F6 MoTDNUBvVS1zMECg{txO M17YN|Q5KGh? NXu5epQ2TUN3ME2wMlA4KM7:TR?= MmnpNVkzOzN2N{C=
L428 MYrDfZRwfG:6aXPpeJkhSXO|YYm= NWq3dZpwOSCwTT2xNFAh|ryP NVjDNoZ1PDhiaB?= MlfvSWM2OD1yLkSzJO69VQ>? M4DIXlE6OjN|NEew
KM-H2 MmC4R5l1d3SxeHnjbZR6KEG|c3H5 NIjsUmUyKG6PLUGwNEDPxE1? MkfCOFghcA>? M1fCTGVEPTB;MD61PEDPxE1? NHTZR|kyQTJ|M{S3NC=>
L540Cy M17NUmN6fG:2b4jpZ4l1gSCDc4PhfS=> M1rwUlEhdk1vMUCwJO69VQ>? NWrpNmtGPDhiaB?= MnuxSWM2OD1yLkG2JO69VQ>? MVOxPVI{OzR5MB?=
G401 M2LKd2Z2dmO2aX;uJGF{e2G7 MXexNEBvVQ>? NE\SW|gzPC92OD:3NkBp NVjhV2NFTE2VTx?= NXjBfFFucW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v M1yzV|E6OjJzNUi2
STM91-01 NWPDbnpMTnWwY4Tpc44hSXO|YYm= MoHpNVAhdk1? Mnz1NlQwPDhxN{KgbC=> Mn;jSG1UVw>? M4PDc4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NVGwUY9zOTl{MkG1PFY>
SJSC  M{ezfWZ2dmO2aX;uJGF{e2G7 NWP4OVRXOTBibl2= MXSyOE81QC95MjDo MoLVSG1UVw>? M2nTPYlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> Mk\zNVkzOjF3OE[=
BT16  NWS2c2FFTnWwY4Tpc44hSXO|YYm= MYexNEBvVQ>? M1;qRlI1NzR6L{eyJIg> NHzwW|dFVVOR NGPjTJZqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NUHKTm5sOTl{MkG1PFY>
NCI-H1299 NEP2ZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDoTWM2OD12LkdCtVAvOiCwZz;tcC=> NXzRXo84OTlzN{m4PVA>
NCI-2882 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn0OnpKSzVyPUGuOuKyOC5yNDDu[{9udA>? M4XXUlE6OTd7OEmw
HCC95 NXzW[3F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwNdMxNE4xPSCwZz;tcC=> NXTvfnNzOTlzN{m4PVA>
NCI-H23 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3PfIxKSzVyPUKuPeKyOC5{IH7nM41t MXWxPVE4QTh7MB?=
NCI-H157 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwNtMxNE4xOiCwZz;tcC=> M3;pPVE6OTd7OEmw
NCI-H460 NIXGSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwMdMxNE4xPyCwZz;tcC=> NYTnelhIOTlzN{m4PVA>
NCI-H1975 M{TwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fVc2lEPTB;MT6zxtExNjB2IH7nM41t NGXrfZIyQTF5OUi5NC=>
NCI-H820 M1LTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXQbG9rUUN3ME2yMlTDuTBwMTDu[{9udA>? MlPQNVkyPzl6OUC=
NCI-H1650 NGXsSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrTTWM2OD12LkpCtVAvOyCwZz;tcC=> MorzNVkyPzl6OUC=
DTC1 NUmzbHY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLhTWM2OD1yLkWxJI5O Mn7GNVg2PjZ{NE[=
KAO NVK2TWE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUKzNHZ2UUN3ME2wMlkyKG6P M4fUT|E5PTZ4MkS2
SU-CCS-1 NGjSUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTzdVlDUUN3ME2wMlg6KG6P MnPiNVg2PjZ{NE[=
SYO-1 NYP6eJlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;WW2lEPTB;MD62O{BvVQ>? MkW1NVg2PjZ{NE[=
FUJI NH3u[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPET41CUUN3ME2xMlMyKG6P NVXBWG04OTh3Nk[yOFY>
SKNMC NWWwW4xGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfnd5NKSzVyPUGuNVchdk1? M{LoSFE5PTZ4MkS2
402-91 NXGwbZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfsS3JKSzVyPUGuNlYhdk1? NICxdGEyQDV4NkK0Oi=>
1765-92 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml33TWM2OD1zLke3JI5O NV;JdIhwOTh3Nk[yOFY>
JN-DSRCT-1 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED3fo1KSzVyPUGuNlUhdk1? NIC3S3cyQDV4NkK0Oi=>
NMS-2PC MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXBPWVKSzVyPUCuPFEhdk1? MWWxPFU3PjJ2Nh?=
HL60 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrlTWM2OD1zLki2JI5O NX7JXJFxOTh3Nk[yOFY>
A549 NHzMOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe2TFdKSzVyPUOuNlQhdk1? M3ji[lE5PTZ4MkS2
SW480 M1zRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXKWHlKSzVyPUKuOlkhdk1? MVOxPFU3PjJ2Nh?=
MCF7 M132XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXUcZdKSzVyPUOuOVUhdk1? NF\4[WoyQDV4NkK0Oi=>
PC-3 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwNUGgcm0> MXSxPFU3PjJ2Nh?=
MMRU MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjLNGJzUUN3ME2yMlU4KG6P M{fJW|E5PTZ4MkS2
Hs68 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPsd4ZVUUN3ME2+NVAhdk1? NIXEcWsyQDV4NkK0Oi=>
hMSC-001F NUe5OYJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRT5zMDDuUS=> NF\HSoQyQDV4NkK0Oi=>

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay
+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research
+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 18 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02850016 Not yet recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital August 2016 Phase 2
NCT02757248 Not yet recruiting PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University July 2016 Phase 1
NCT02281279 Not yet recruiting B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia Mayo Clinic|National Cancer Institute (NCI) June 2016 Phase 1|Phase 2
NCT02783625 Recruiting Lymphoma|Relapsed/Refractory T-cell Lymphomas Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Stanford University May 2016 Phase 1
NCT02616874 Recruiting HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN-Checkpoint February 2016 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation December 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID